Clinical Trial: GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07871435) titled 'GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)' on Oct. 01.

Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).

Study Start Date: Oct. 12

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Intervention: DRUG: GI-102...